MONTREAL, QUEBEC--(Marketwire - December 10, 2007) - Ambrilia Biopharma Inc. (TSX: AMB) announced today that Jean-Paul St-Pierre, M.D., has joined the Board of Directors of the Company.
"I wish to welcome Dr. St-Pierre, who is a talented executive in drug research and development management in the biotechnology and pharmaceutical industries, as a new member of the Board", said Frederic Porte, Chairman of the Board of Ambrilia. "His know-how in building and maximizing R&D capabilities as well as his expertise in design and implementation of drug discovery and development strategies will be value-added assets to Ambrilia's execution of its new strategic plan", he concluded.
